Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor α convertase inhibitors

Protein Science

Volumn 7, Issue 2, 1998, Pages 283-292

  Gomis Rüth, F Xavier ^a   Meyer, Edgar F ^b   Kress, Lawrence F ^c   Politi, Vincenzo ^d  

^a Ctr d'Investigacio i D   (Spain)

^b TEXAS A AND M UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Polifarma Res Centre   (Italy)

Author keywords

ADAM; Adamalysin; Snake venom prokinase; X ray structure; Zinc endopeptidase

Indexed keywords

ADAMALYSIN; ADAMALYSIN 2; CONVERTASE; METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC;

ARTICLE; CHEMICAL STRUCTURE; COMPUTER MODEL; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; SNAKE; STRUCTURE ANALYSIS;

EID: 0039122255     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560070207     Document Type: Article

References (55)

1. Alfandari D, Wolfsberg TG, White JM, Desimone DW. 1997. ADAM 13 - A novel ADAM expressed in somatic mesoderm and neural crest cells during Xenopus laevis development. Dev Biol 182:314-330.
2. Bjamason JB, Fox JB. 1994. Hemorrhagic metalloproteinases from snake venoms. Pharmac Ther 62:325-372.
3. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinavasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton R, March CJ, Cerretti DP. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385:729-733.
4. Bode W, Gomis-Rüth FX, Stöcker W. 1993. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the "metzincins." FEBS Lett 331:134-140.
5. Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H. 1994. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J 13:1263-1269.
6. Botos I, Zhang D, Scapozza L, Liotta LA, Meyer EF. 1996. Batimastat, a potent matrix metalloproteinase inhibitor with an unexpected mode of binding. Proc Natl Acad Sci USA 93:2749-2754.
7. Brünger AT. 1991. Crystallographic phasing and refinement of macromolecules. Curr Opin Struct Biol 1:1016-1022.
8. Catanese JJ, Kress LF. 1992. Isolation from opossum serum of a metalloproteinase inhibitor homologous to human α1β-glycoprotein. Biochemistry 37:410-418.
9. CCP4. 1994. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D 50:760-763.
10. Cheung HS, Chrisman DW. 1973. Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca. Biochim Biophys Acta 293:451-459.
11. Emi M, Katagiri T, Hrada Y, Saito H, Inazawa J, Ito I, Kasumi F, Nakamura Y. 1993. A novel metalloprotease/disintegrin-like gene at 17q21.3 is somatically rearranged in two primary breast cancers. Nature Genet 5:151-157.
12. Engh RA, Huber R. 1991. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr A 47:392-400.
13. Ferreira SH. 1965. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 24:163-171.
14. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Well G, Wood LM, Woolley K. 1994. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370:555-557.
15. Gilardini-Montani MS, Tousto L, Delfini M, Guerritore D, Starace G, Politi V, Piccolella E. 1993. A new tripeptide, Pol509, influences biochemical events associated with antigen presentation efficiency of PPD-specific EBV-B cells. Immunopharmacol 25:51-63.
16. Gomis-Rüth FX, Kress LF, Bode W. 1993. First structure of a snake venom metalloproteinase: A prototype for matrix metalloproteinases/collagenases. EMBO J 12:4151-4157.
17. Gomis-Rüth FX, Kress LF, Kellermann J, Mayr I, Lee X, Huber R, Bode W. 1994. Refined 2.0 Å X-ray crystal structure of the zinc-endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin. J Mol Biol 239:513-544.
18. Grams F, Dive V, Yiotakis A, Yiallouros I, Vassiliou S, Zwilling R, Bode W, Stöcker W. 1996. Structure of astacin with a transition-state analogue inhibitor. Nature Struct Biol 3:671-675.
19. Grams F, Huber R, Kress LF, Moroder L, Bode W. 1993. Activation of snake venom metalloproteinases by a cysteine switch-like mechanism. FEBS Lett 335:76-80.
20. Grams F, Reinemer P, Powers JC, Kleine T, Pieper M, Tschesche H, Huber R, Bode W. 1995. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. Eur J Biochem 225:830-841.
21. Hite LA, Fox JW, Bjarnason JB. 1992. A new family of proteinases is defined by several snake venom metalloproteinases. Biol Chem Hoppe-Seyler 373:381-385.
22. Hite LA, Jia LG, Bjarnason JB, Fox JW. 1994. cDNA sequences for four snake venom metalloproteinases: Structure, classification, and their relationship to mammalian reproductive proteins. Arch Biochem Biophys 305:182-191.
23. Huovila APJ, Almeida EAC, White JM. 1996. ADAMS and cell fusion. Curr Opin Cell Biol 8:692-699.
24. Kester WR, Matthews BW. 1977. Crystallographic study of dipeptide inhibitors to thermolysin: Implications for the mechanism of catalysis. Biochemistry 16:2506-2516.
25. Kini RM, Evans HJ. 1992. Structural domains in venom proteins: Evidence that metalloproteinases and nonenzymatic platelet aggregation inhibitors (disintegrins) from snake venom are derived by proteolysis from a common precursor. Toxicon 30:265-293.
26. Kraulis PJ. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24:946-950.
27. Kress LF. 1986. Inactivation of human plasma serine proteinase inhibitors (serpins) by limited proteolysis of the reactive site loop with snake venom and bacterial metalloproteinases. J Cell Biochem 32:51-58.
28. Kress LF, Catanese JB. 1981. Identification of the cleavage sites resulting from enzymatic inactivation of human antithrombin III by Crotalus adamanteus proteinase II in the presence and absence of heparin. Biochemistry 20:7432-7438.
29. 2-proteinase from the venom of Trimeresurus flavoviridis. J Biochem 119:49-57.
30. 1-proteinase inhibitor. J Biol Chem 253:8340-8345.
31. Kurisu G, Kinoshita T, Sugimoto A, Nagara A, Kai Y, Kasai N, Harada S. 1997. Structure of the zinc endoprotease from Streptomyces caespitosus. J Biochem 121:304-308.
32. Laing G, Politi V. 1995. A peptido-mimetic inhibitor neutralises the haemorrhagic and lethal activities of Echis carinatus laekeyi venom. Toxicon 33:261-261.
33. Lunn CA, Fan XD, Dalie B, Miller K, Zavodny PJ, Narula SK, Lundell D. 1997. Purification of ADAM 10 from bovine spleen as aTNF-α convertase. FEBS Lett 400:333-335.
34. Matthews BW. 1988. Structural basis of the action of thermolysin and related zinc peptidases. Acc Chem Res 27:333-340.
35. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB. Nichols J, Pryzwanski KM, Schoenen F, Sekut L, Truesdale A, Verghese M, Warner J, Ways JP. 1994. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370:558-561.
36. Messerschmidt A, Pflugrath JW. 1987. Crystal orientation and X-ray pattern prediction routines for area detector diffractometer systems in macromolecular crystallography. J Appl Crystallogr 20:306-315.
37. Messerschmidt A, Schneider M, Huber R. 1990. ABSCOR: A scaling and absorption correction program for the FAST area detector. J Appl Crystallogr 23:436-439.
38. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawama K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ, Black RA. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor-α processing. Nature 370:218-220.
39. Moss ML, Jin SLC, Milla ME, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Willard D, Becherer D. 1997. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 385:733-736.
40. Moura da Silva AM, Laing GD, Paine MJI, Dennison JMTJ, Politi V, Crampton JM, Theakston RDG. 1996. Processing of pro-tumor necrosis factor-α by venom metalloproteinases: A hypothesis explaining local tissue damage following snake bite. Eur J Immunol 26:2000-2005.
41. Neeper MP, Jacobson MA. 1990. Sequence of a cDNA encoding the platelet aggregation inhibitor trigramin. Nucleic Acids Res 18:4255-4255.
42. Nomura K, Suzuki N. 1993. Stereo-specific inhibition of sea urchin envelysin (hatching enzyme) by a synthetic autoinhibitor peptide with a cysteine-switch consensus sequence. FEBS Lett 321:84-88.
43. Robeva A, Politi V, Shannon JD, Bjarnason JB, Fox JW. 1991. Synthetic and endogenous inhibitors of snake venom metalloproteinases. Biomed Biochim Acta 50:769-773.
44. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. 1995. Tumour necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: An expanded therapeutic window. Brain Res 703:151-155.
45. Schechter I, Berger A. 1967. On the size of active site in proteases. I. Papain. Biochem Biophys Res Commun 27:157-162.
46. Schlagenhauf E, Etges R, Metcalf P. 1995. Crystallization and preliminary X-ray diffraction studies of leishmanolysin, the major surface metalloproteinase from Leishmania major. Proteins Struct Funct Genet 22:58-66.
47. Shannon JD, Baramova EN, Bjamason JB, Fox JW. 1989. Amino acid sequence of a Crotalus atrox venom metalloproteinase which cleaves type IV collagen and gelatin. J Biol Chem 264:175-190.
48. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. 1990. Multiple modes of activation of latent human fibroblast collagenase: Evidence for the role of Cys 73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci USA 87:364-368.
49. Steigemann W. 1991. Crystallographic computing. In: Moras D, Podjarni AD, Thierry JC, eds. From chemistry to biology 5. Oxford: Oxford University Press. pp 115-125.
50. Stocker W, Grams F, Baumann U, Reinemer P, Gomis-Ruth FX, McKay DB, Bode W. 1995. The metzincins - Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci 4:823-840.
51. Wolfsberg TG, Primakoff P, Myles DG, White JM. 1995a. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain - Multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 131:215-278.
52. Wolfsberg TG, Straight PD, Gerena RL, Huovila APJ, Primakoff P, Myles DG, White JM. 1995b. ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with A Disintegrin And Metalloprotease domain. Dev Biol 169:378-383.
53. Wolfsberg TG, White JM. 1996. ADAMs in fertilization and development. Dev Biol 180:389-401.
54. Yamakawa Y, Omori-Satoh T. 1992. Primary structure of the antihemorrhagic factor in serum of the Japanese habu: A snake venom metalloproteinase inhibitor with a double-headed cystatin domain. J Biochem 112:583-589.
55. Zhang D, Botos I, Gomis-Rüth FX, Doll R, Blood C, Njoroge FG, Fox JW, Bode W, Meyer EF. 1994. Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d). Proc Natl Acad Sci USA 97:8447-8451.